Results 21 to 30 of about 562,472 (163)

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary [PDF]

Journal of Comparative Effectiveness Research
What is this summary about? This is a plain language summary of a published article in the journal Sleep. Narcolepsy is a sleep condition that has 2 different subtypes: narcolepsy type 1 and narcolepsy type 2. These are called NT1 and NT2 for short.
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Fèri Ascencion, Jennifer Gudeman   +6 more
doaj   +2 more sources

Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy. [PDF]

J Sleep Res
ABSTRACT Data from the REST‐ON trial were not available before the 2021 American Academy of Sleep Medicine (AASM) clinical practice guideline update, which included a literature review through August 2020. This post hoc analysis from REST‐ON assessed participants who achieved clinically significant improvements on individual AASM clinical significance ...
Ortiz LE, Morse AM, Thorpy MJ, Kushida CA, Harsh J, Roth T, Gudeman J, Dauvilliers Y.   +7 more
europepmc   +2 more sources

Sleep, Narcolepsy, and Sodium Oxybate [PDF]

Current Neuropharmacology, 2022
Mortimer Mamelak
exaly   +2 more sources

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

Neurology and Therapy, 2023
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg, Rogelio Braceras, Wayne Macfadden, Shawn Candler, Jed Black, Chad Ruoff   +5 more
doaj   +1 more source

Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System

Drugs - Real World Outcomes, 2023
Introduction Sodium oxybate has been approved by the US Food and Drug Administration (FDA) to treat narcolepsy for 20 years; however, the only available products have been immediate-release (IR) formulations given twice nightly—once at bedtime and a ...
Jennifer Gudeman, Danielle Burroughs
doaj   +1 more source

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies

Clinical and Translational Science, 2021
American Academy of Sleep Medicine practice parameters designate sodium oxybate (SXB) as a standard of care for cataplexy, excessive daytime sleepiness (EDS), and disrupted night‐time sleep in narcolepsy.
Cuiping Chen, Jack Jenkins, Katie Zomorodi, Roman Skowronski   +3 more
doaj   +1 more source

Sodium oxybate

Reactions Weekly
Dominguez A, Soca Gallego L, Patel P, Parmar M.   +3 more
europepmc   +4 more sources

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.

PLoS ONE, 2023
PurposeThe US Food and Drug Administration (FDA) Amendments Act of 2007 authorized the FDA to require risk evaluation and mitigation strategy (REMS) programs for drugs with important safety concerns.
Ameet Sarpatwari, Beatrice L Brown, Sarah A McGraw, Sara Z Dejene, Abdurrahman Abdurrob, Aaron S Kesselheim   +5 more
doaj   +1 more source

Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective

Nature and Science of Sleep, 2023
Asim Roy,1 Diane Ito,2 Susan Morris,3 Shawn Candler,4 Judi Profant,3 Charles Bae5 1Ohio Sleep Medicine Institute, Dublin, OH, USA; 2Stratevi LLC, Santa Monica, CA, USA; 3Jazz Pharmaceuticals, Palo Alto, CA, USA; 4Jazz Pharmaceuticals, Philadelphia, PA ...
Roy A, Ito D, Morris S, Candler S, Profant J, Bae C   +5 more
doaj